Akorn, Inc. (NASDAQ:AKRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday. According to Zacks, “Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. They also market ophthalmic surgical instruments and related […] - From Sports Perspectives
Catalyst Capital Advisors LLC raised its position in shares of Akorn by 400.0% in the third quarter.
Catalyst Capital Advisors LLC now owns 4,000 shares of the company’s stock worth $109,000 after buying an additional 3,200 shares during the period.
LS Investment Advisors LLC now owns 6,204 shares of the company’s stock worth $169,000 after buying an additional 644 shares during the period.
now owns 9,034 shares of the company’s stock worth $246,000 after buying an additional 1,593 shares during the period.
Oakbrook Investments LLC now owns 9,050 shares of the company’s stock worth $247,000 after buying an additional 1,400 shares during the period.